Kubotek Selected for 2.5 Billion KRW Ministry of Trade, Industry and Energy Project: "Development of Mixed Materials for Esthetic Prosthetics"

Kubotek, a specialized dental medical device company, announced on the 21st that it has successfully secured a total of 4.5 billion KRW in government research and development funding and commercialization capital from Bright Asset Management, a member company of the Ministry of Trade, Industry and Energy (MOTIE) and the Korea Institute for Technology Investment Association (KITIA).

Kubotek was recognized for its innovative technology and continuous R&D achievements and was selected as a supported company for the 2024 Materials and Components Technology Development Project (Heterogeneous Technology Convergence Type) by the Korea Institute for Advancement of Technology (Keit), an organization under MOTIE. It will receive a total of 2.5 billion KRW in government funding over two and a half years.

The selected project is titled "Development of High-Strength and High-Transmittance Aesthetic Prosthetic Ceramic Printing Materials and Processes Using Alkaline Silicate-Based Oxides," applying a photopolymerization ceramic 3D printing method capable of achieving high resolution and precise surface shapes. The project aims to develop a mixed material for dental aesthetic prosthetics with high flexural strength and light transmittance properties. During the project period, it plans to obtain approval by verifying the safety and efficacy of the medical device through the Ministry of Food and Drug Safety and to achieve early commercialization.

Additionally, by proving its technological capability and business potential through this project, Kubotek attracted an investment of 2 billion KRW from Bright Asset Management, a specialized IPO management firm. The investment consists of 1 billion KRW in Redeemable Convertible Preferred Shares (RCPS) and 1 billion KRW in Convertible Bonds (CB). Bright Asset Management is an IPO-focused management company that actively participates not only in public offerings but also in SPAC sponsorship and pre-IPO investments.

Kubotek’s strategy is to develop innovative new technologies through this project to contribute to the advancement of domestic medical technology and industry and to further strengthen its technological competitiveness. The funds raised from Bright Asset Management will be primarily invested in facility expansion and promotion/marketing.

Jung Cheol-woong, CEO of Kubotek, stated, "Based on consecutive achievements such as selection for cross-ministerial projects and investment attraction, we will expand research and development (R&D) investment and production capacity (CAPA) and enhance sales capabilities to maximize the company’s competitiveness." He added, "Through this, we expect to lay the foundation for pursuing an IPO in the future."

Kubotek, established in 2007, is a specialized dental medical device company providing total dental solutions including dental implants, digital ceramic prosthetic materials, and products related to oral and periodontal diseases. The company has developed both implant and zirconia prosthetic materials independently.

Kubotek implants have confirmed clinical safety for nearly 10 years and have been used for extended periods in various clinical institutions, including university hospitals. In particular, the new product TLPLANT is a digital-friendly integrated implant with a minimal diameter. It is resistant to inflammation and fracture and can be implanted without bone grafting even in narrow alveolar bone widths, making it highly praised in the market as an implant suitable for the digital and ultra-miniaturization era.

In overseas export markets, Kubotek has obtained the stringent European certification and is achieving significant results in Eastern Europe based in Poland. It exports to 16 countries worldwide. Currently, it is pursuing Chinese certification aiming to enter the Chinese market. As of the end of 2023, it achieved sales of approximately 9 billion KRW.

Currently, through years of independent R&D, Kubotek is commercializing zirconia crown materials for 3D printing and has developed the world’s first dental implant surface treatment process using chlorides, targeting commercialization in the first half of 2025.